The Perioperative Value of Platelet Counts in Predicting Outcome After Liver Transplantation
- Conditions
- DeathComplication
- Interventions
- Procedure: Liver transplantation
- Registration Number
- NCT01711957
- Lead Sponsor
- University of Zurich
- Brief Summary
Recent experimental and clinical studies have shown that platelets play a critical role in liver ischemia and regeneration. Thrombocytopenia, a frequent and potentially serious condition in liver transplantation (LT) recipients, was shown to be associated with postoperative morbidity and mortality after partial hepatectomy.
The investigators aim at evaluating whether postoperative low platelet counts are indicators of short- and long-term outcomes after liver transplantation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 250
- Age >18 years old
- End stage liver disease
- Cadaveric-donor liver transplantation
- Age <18 years old
- Pregnancy
- Living-related liver transplantation
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Liver disease and liver transplantation Liver transplantation Patient with end stage liver disease and/or primary liver tumor undergoing liver transplantation
- Primary Outcome Measures
Name Time Method Severe complication after liver transplantation 90 days The severity of complications will be graded according to the Clavien-Dindo classification by outcome. Grade III to V complications will be considered as severe.
- Secondary Outcome Measures
Name Time Method Delayed graft function 7 days after liver transplantation Defined as the presence of at least one of the following parameter at 7 days after LT: serum bilirubin \> 10 mg/dL and International Normalized Ratio (INR) \>1.6 or Alanine aminotransferase serum level (ALT) \>2000UI/L
Primary graft non-function first postoperative week Defined as death or retransplantation within the first postoperative week after exclusion of technical, immunological, and infectious causes
Trial Locations
- Locations (1)
University Hospital Zurich, Department of Visceral Surgery and Transplantation
🇨ðŸ‡Zurich, Switzerland